Woburn, MA (PRWEB) November 30, 2005
Pluromed Inc., a private medical device company that may revolutionize hemostasis during surgery and interventional procedures, announced today that James A. Wilkie, 42, former President and CEO of Surgical Sealants Inc., has joined the company full-time as Vice-President, Operations.
"Jim brings focus to our operations and regulatory processes, which are critical for FDA and European market approval", said Jean-Marie Vogel, Pluromed’s CEO and cofounder. "His general management capabilities, entrepreneurial nature and extensive experience in R&D, operations, product development and regulatory affairs make him ideally suited for this position. Much of his experience has been with closely related polymer-based devices.”
Mr. Wilkie joins Pluromed from Conmed Endoscopic Technologies. Prior to co-founding Surgical Sealants at the age of 33, he was Director of R&D & Engineering for Medchem Products and part of the team that sold MedChem to C.R. Bard. Mr. Wilkie has a degree in Plastics Engineering from the University of Massachusetts, Lowell.
“I am very excited to help Pluromed bring its initial product to market” stated Mr. Wilkie. “The Company is developing great products that have applications in many growth areas, including interventional cardiology and “key-hole” surgery, and a number of more classical surgical procedures. I think the Company has a big future ahead of it and I'm happy to be able to add my skill set to an area in which I have a strong personal interest."
On November 22 the Company announced that 7 CEOs, former CE0s and founders of US medical device companies have invested in the initial close of its current Series A Convertible Preferred Stock Offering.
Pluromed has developed LeGoo™, a unique and patent protected medical device to manage bleeding during surgery and interventional procedures. LeGoo™ is completely atraumatic, and appears to have many additional valuable applications beyond the Company’s initial cardiovascular and urology markets. Pluromed has carried out extensive preclinical testing in the U.S., Canada and Europe, which it plans to follow in 2006 with clinical studies in major medical centers.
Pluromed was founded in 2003 by Jean-Marie Vogel, formerly founder and Chairman of BioSphere Medical and Cryoma Laboratories, and previously a sales and marketing executive with Sepracor and Millipore Corporation; and by Dr. Alexander Schwarz, formerly Research Director of BioSphere Medical, an expert in vascular applications of polymers. The Company has production and office facilities in Woburn, Massachusetts.
This press release does not constitute an offer to sell or solicitation of an offer to buy the company’s preferred stock in any jurisdiction, nor does it constitute any endorsement of the company by any investors beyond their decision to invest. Shares of Pluromed Series A Convertible Preferred Stock are only being offered in a private placement under Regulation D under the Securities Act of 1933, as amended, and private placement exemptions from the registration and qualification requirements of applicable state securities laws and only to investors who are “accredited investors” and who otherwise meet the suitability requirements set forth in the company’s Confidential Private Offering Memorandum.
# # #